Eli Lilly (LLY)
(Delayed Data from NYSE)
$808.45 USD
+5.54 (0.69%)
Updated May 23, 2024 04:00 PM ET
After-Market: $808.20 -0.25 (-0.03%) 4:54 PM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Brokerage Reports
Eli Lilly and Company [LLY]
Reports for Purchase
Showing records 21 - 40 ( 428 total )
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended November 17.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 111123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 11123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 102123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 101123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 10123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended September 15.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 92123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 91123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended August 25.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for LLY 9123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended August 18.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D